| 1493 |
National Cancer Institute |
Html |
en |
Oropharyngeal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of oropharyngeal cancer. |
| neck radiotherapy | 0.359364 |
| locally advanced head | 0.471621 |
| Engl J Med | 0.53665 |
| American Cancer Society | 0.443811 |
| well-lateralized oropharyngeal cancer | 0.401103 |
| neck radiation therapy | 0.384516 |
| Int J Radiat | 0.508851 |
| neck cancer patients | 0.486158 |
| squamous cell cancer | 0.411067 |
| Radiat Oncol Biol | 0.753309 |
| DeVita VT Jr | 0.383261 |
| Natl Cancer Inst | 0.447951 |
| neck cancers | 0.433823 |
| Clin Cancer Res | 0.390283 |
| radiation therapy | 0.610067 |
| human papillomavirus | 0.44587 |
| smoking-related oropharyngeal cancer | 0.443579 |
| HPV-positive oropharyngeal cancer | 0.448716 |
| et al. | 0.570118 |
| Mendenhall WM | 0.369324 |
| Cancer Genet Cytogenet | 0.359903 |
| Head Neck | 0.484421 |
| index nonoropharyngeal cancer | 0.350094 |
| Oropharyngeal tumors | 0.352557 |
| index oropharyngeal SCC | 0.386084 |
|
| neck SCC | 0.359598 |
| oropharyngeal cancers | 0.476599 |
| HPV-positive oropharyngeal cancers | 0.469127 |
| anterior tonsillar pillar | 0.378606 |
| Cancer Epidemiol Biomarkers | 0.378376 |
| neck squamous cell | 0.377126 |
| head | 0.534685 |
| PUBMED Abstract | 0.462256 |
| early-stage oropharyngeal cancer | 0.392101 |
| Otolaryngol Head Neck | 0.404239 |
| index oropharyngeal cancers | 0.372661 |
| -positive oropharyngeal cancers | 0.363257 |
| neck retinoid chemoprevention | 0.355793 |
| Abstract | 0.60039 |
| Clin Oncol | 0.357598 |
| Oncol Biol Phys | 0.772447 |
| squamous cell carcinomas | 0.385763 |
| primary tumor | 0.372966 |
| field cancerization | 0.370643 |
| neck cancer | 0.957961 |
| neck tumors | 0.340144 |
| oropharyngeal cancer | 0.807108 |
| oropharyngeal SCC | 0.391565 |
| oropharyngeal cancer incidence | 0.417437 |
|
CLICK HERE |
| 1558 |
National Cancer Institute |
Html |
en |
Endometrial Cancer Prevention (PDQ®)–Patient Version |
Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease. |
| cancer treatment | 0.459672 |
| cancer prevention trials | 0.519855 |
| estrogen | 0.503683 |
| endometrial cancer prevention | 0.633127 |
| protective factors | 0.494311 |
| following PDQ summaries | 0.487054 |
| PDQ cancer information | 0.583616 |
| estrogen receptor modulators | 0.479388 |
| oral contraceptives increases | 0.455046 |
| uterus | 0.455824 |
| clinical trials | 0.591442 |
| cancer information summary | 0.536389 |
| breast cancer prevention | 0.515055 |
| cancer patients | 0.456862 |
| cancer risk factor | 0.514935 |
| NCI’s PDQ | 0.460213 |
| metabolic syndrome | 0.469608 |
| Clinical Trials section | 0.455747 |
| NCI PDQ cancer | 0.511939 |
| endometrial hyperplasia | 0.525569 |
| hormone replacement therapy | 0.4814 |
| new cases | 0.45495 |
| estrogen levels | 0.496361 |
| cancer risk factors | 0.513284 |
|
| Cancer prevention | 0.648371 |
| cancer protective factor | 0.491722 |
| high estrogen levels | 0.479463 |
| Cancer Information Service | 0.48404 |
| polycystic ovary syndrome | 0.484739 |
| prevention clinical trials | 0.493334 |
| Prevention Editorial Board | 0.485326 |
| treatment clinical trials | 0.456257 |
| National Cancer Institute | 0.542099 |
| endometrial cancer | 0.951484 |
| African American women | 0.525683 |
| estrogen therapy | 0.459908 |
| higher risk | 0.454955 |
| postmenopausal women | 0.557323 |
| Cancer Care page | 0.476271 |
| PDQ database | 0.456704 |
| PDQ summary | 0.495085 |
| combination oral contraceptives | 0.477913 |
| cancer clinical trials | 0.489805 |
| risk factors | 0.587492 |
| nonpolyposis colon cancer | 0.481746 |
| cancer information summaries | 0.48866 |
| comprehensive cancer information | 0.488387 |
| risk | 0.63452 |
|
CLICK HERE |
| 1846 |
National Cancer Institute |
Html |
es |
Tratamiento del carcinoma de corteza suprarrenal (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del carcinoma de corteza suprarrenal. |
| Compton CC | 0.317328 |
| Hammer GD | 0.357944 |
| resection vs chemotherapy | 0.309791 |
| Sin embargo | 0.386449 |
| estadificación ensat | 0.311064 |
| largo plazo | 0.314068 |
| treatment utilization | 0.307637 |
| 7th ed | 0.317264 |
| estadificación ajcc | 0.311961 |
| corteza suprarrenal benignos | 0.333736 |
| adrenal cortical carcinoma | 0.326878 |
| Instituto Nacional | 0.323164 |
| Radiat Oncol Biol | 0.331552 |
| Zaggia B | 0.315343 |
| Ardito A | 0.314362 |
| Terzolo M | 0.35082 |
| Basic Science | 0.331876 |
| Else T | 0.335075 |
| Clinical review | 0.338841 |
| corteza suprarrenal benignas | 0.333037 |
| ENSAT staging system | 0.311888 |
| Arch Surg | 0.319608 |
| Griffith K | 0.315391 |
| Feng M | 0.318852 |
| Fassnacht M | 0.481992 |
|
| Clin Endocrinol Metab | 0.365561 |
| estadio ii | 0.316817 |
| metástasis pulmonar | 0.312599 |
| Pfreundner L | 0.316104 |
| Angeli A | 0.316386 |
| Cancer Staging Manual | 0.333671 |
| adrenocortical carcinoma using | 0.342814 |
| National Cancer Institute | 0.309404 |
| PDQ Tratamiento | 0.316742 |
| New York | 0.405075 |
| Physician Data Query | 0.30836 |
| adrenocortical carcinoma | 0.972403 |
| Oncol Biol Phys | 0.332857 |
| Langenbecks Arch Surg | 0.312314 |
| Allolio B | 0.353761 |
| with adrenocortical carcinoma | 0.336171 |
| Byrd DR | 0.316426 |
| Union Internationale Contre | 0.309764 |
| American Joint Committee | 0.309683 |
| Sabolch A | 0.315391 |
| Ther Phys Biol | 0.311534 |
| Recurrent or metastatic | 0.308748 |
| Clinical Concepts | 0.340059 |
| AJCC Cancer Staging | 0.33628 |
|
CLICK HERE |
| 1881 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de Ewing (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del Sarcoma de Ewing. |
| ewing sarcoma | 0.997403 |
| Ewing family | 0.318421 |
| Ewing's sarcoma family | 0.369762 |
| metastatic ewing sarcoma | 0.318472 |
| ewing óseo valor | 0.311245 |
| skeletal localized ewing | 0.310397 |
| Ewing Grupo | 0.309837 |
| non-metastatic ewing | 0.310313 |
| Ewing's Sarcoma Studies | 0.319442 |
| ewing óseo caracterÃstica | 0.311302 |
| Ewing extraóseo | 0.331665 |
| Ewing sarcoma demonstrates | 0.319966 |
| Ewing sarcoma with | 0.320002 |
| localized ewing tumours | 0.310538 |
| localized ewing | 0.369471 |
| ewing-like sarcomas | 0.313809 |
| Children's Oncology Group | 0.332597 |
| ewing sarcoma family | 0.424972 |
| Ewing sarcoma patients | 0.320654 |
| with ewing | 0.35586 |
| Ewing's tumors with | 0.311931 |
| Ewing Sarcoma Study | 0.321953 |
| with localized ewing | 0.320841 |
| primary ewing | 0.310256 |
| extraskeletal ewing sarcoma | 0.318994 |
|
| Ewing's Sarcoma Study | 0.335323 |
| synovial sarcoma | 0.309759 |
| cooperative ewing sarcoma | 0.431437 |
| Ewing sarcoma under | 0.319395 |
| EWSR1-rearranged Ewing | 0.309748 |
| localized ewing tumor | 0.320103 |
| ewing extraóseo sarcoma | 0.320923 |
| osseous ewing | 0.30998 |
| Pediatr Blood Cancer | 0.363663 |
| ewing sarcoma defines | 0.332159 |
| Intergroup Cooperative Ewing | 0.343374 |
| Ewing Sarcoma Studies | 0.337882 |
| Genes Chromosomes Cancer | 0.320148 |
| ewing's sarcoma | 0.626467 |
| Ewing óseo | 0.324425 |
| gen ewsr1 | 0.309831 |
| ewing's tumors | 0.326472 |
| secondary ewing | 0.310067 |
| Pediatr Hematol Oncol | 0.310262 |
| Clin Oncol | 0.365031 |
| multifocal ewing sarcoma | 0.318953 |
| ewing tumors | 0.399514 |
| congenital ewing sarcoma | 0.318921 |
| Ewing sarcoma susceptibility | 0.318556 |
|
CLICK HERE |
| 2071 |
National Cancer Institute |
Html |
es |
Cirugía para reducir el riesgo de cáncer de seno |
Hoja informativa que describe las clases de cirugía para reducir el riesgo de cáncer de seno y las situaciones en las que se puede pensar en esas operaciones. |
| Surgical Adjuvant Breast | 0.526694 |
| PROSE Study Group | 0.516256 |
| cáncer invasor | 0.567762 |
| brca1 or brca2 | 0.538495 |
| mastectomÃa subcutánea | 0.530865 |
| Preventing breast | 0.511838 |
| Breast Cancer Research | 0.523551 |
| risk-reducing surgery | 0.507962 |
| with brca1 or | 0.509298 |
| brca2 mutation | 0.564149 |
| breast screening with | 0.51472 |
| Preventive Services Task | 0.512338 |
| mastectomy reduces breast | 0.516804 |
| alta penetrancia | 0.508455 |
| risk after smaller | 0.509063 |
| Friebel T | 0.508008 |
| PubMed Abstract | 0.952028 |
| Clinical Oncology | 0.653359 |
| Cancer Journal | 0.515034 |
| BRCA2 mutation carriers | 0.554396 |
| early breast cancer | 0.539203 |
| ¿Cuáles mujeres | 0.517292 |
| bilateral mastectomy | 0.517477 |
| BRCA2 mutations detected | 0.508495 |
| alto riesgo | 0.656597 |
|
| Wickerham DL | 0.51571 |
| an overview | 0.508367 |
| Costantino JP | 0.515178 |
| Cancer Risk Assessment | 0.519342 |
| Rebbeck TR | 0.508232 |
| developing invasive breast | 0.513495 |
| antecedentes familiares | 0.554456 |
| riesgo promedio | 0.539499 |
| or brca2 mutations | 0.536318 |
| breast cancer risk | 0.617067 |
| mutation carriers with | 0.509322 |
| gen pten | 0.510383 |
| breast cancer | 0.801718 |
| Breast Cancer Trialists | 0.522907 |
| Services Task Force | 0.511925 |
| prophylactic mastectomy | 0.591377 |
| mujeres portadoras | 0.533011 |
| gen brca1 | 0.561202 |
| contralateral prophylactic mastectomy | 0.534028 |
| Cancer Institute | 0.511805 |
| Clinical Cancer Research | 0.516971 |
| gen brca2 | 0.561192 |
| gen tp53 | 0.518098 |
| New England Journal | 0.535054 |
|
CLICK HERE |
| 3413 |
National Cancer Institute |
Html |
en |
Treatment Prevents Chemotherapy Side Effects for Children with Cancer |
Adding aprepitant to the anti-nausea drug ondansetron, with or without dexamethasone, effectively prevents chemotherapy-induced nausea and vomiting in children. |
| Lancet Oncology | 0.402095 |
| approximately one-quarter | 0.400434 |
| Approximately half | 0.380915 |
| individual chemotherapy regimens | 0.640029 |
| pediatric oncologists | 0.386544 |
| primary endpoint | 0.376989 |
| accompanying editorial | 0.359286 |
| control group | 0.648089 |
| chemotherapy | 0.797555 |
| highly emetogenic chemotherapy | 0.635176 |
| pediatric patients | 0.446593 |
| pediatric dosing | 0.38895 |
| cancer therapy | 0.375879 |
| South Korea | 0.360387 |
| Final results | 0.390611 |
| poorer outcomes | 0.360045 |
| delayed phase | 0.536277 |
| well-designed anti-emetic study | 0.496684 |
| children | 0.367409 |
| pediatric anti-emetic regimens | 0.524869 |
| steroid dexamethasone | 0.449436 |
| retrospective reports | 0.357625 |
| Hyoung Jin Kang | 0.507923 |
| treatment-limiting complications | 0.376302 |
|
| moderate risk | 0.374131 |
| Richard Gralla | 0.361364 |
| vomiting | 0.627585 |
| anti-nausea drug | 0.394817 |
| clinical trial | 0.39616 |
| chemotherapy-induced nausea | 0.735879 |
| Fifty-one percent | 0.401703 |
| cancer patients | 0.390213 |
| trial results | 0.359251 |
| aprepitant group | 0.947977 |
| complete response | 0.53189 |
| study medications | 0.371063 |
| febrile neutropenia | 0.569771 |
| Seoul National University | 0.506591 |
| neurokinin-1 receptor antagonist | 0.536858 |
| serotonin receptor | 0.391814 |
| neutrophil count | 0.368149 |
| Pediatric Oncology Branch | 0.516455 |
| chemotherapy regimen patients | 0.648708 |
| antiemetic rescue medication—medication | 0.520408 |
| common adverse events | 0.501689 |
| Secondary endpoints | 0.373589 |
| Melinda Merchant | 0.355445 |
|
CLICK HERE |
| 3432 |
National Cancer Institute |
Html |
es |
Formaldehído y el riesgo de cáncer |
Hoja informativa que trata sobre el formaldehído y su posible relación con el cáncer. Incluye recursos para consultar mayor información. |
| leucemia mieloide | 0.978153 |
| malignancies among workers | 0.549063 |
| TW Alexander Drive | 0.542382 |
| exterior-grade” pressed-wood | 0.527538 |
| cancers among workers | 0.548254 |
| Programa Nacional | 0.567373 |
| largo plazo | 0.580439 |
| Protección Ambiental | 0.673926 |
| Salud Ocupacional | 0.583378 |
| Mortality from | 0.576068 |
| Instituto Nacional | 0.645898 |
| Indoor Air | 0.527731 |
| pequeñas cantidades | 0.52948 |
| Lubin JH | 0.573228 |
| posibles efectos | 0.584035 |
| Estados Unidos | 0.527658 |
| PubMed Abstract | 0.744149 |
| Cancer Institute Cohort | 0.547453 |
| East West Highway | 0.542743 |
| International Agency | 0.53583 |
| Environmental Protection Agency | 0.819165 |
| probable carcinógeno | 0.619447 |
| Product Safety Commission | 0.830336 |
| among workers | 0.572581 |
| New Hampshire Avenue | 0.541693 |
|
| aislamiento uffi | 0.536299 |
| National Toxicology Program | 0.804784 |
| Drug Administration | 0.579636 |
| Environmental Health Sciences | 0.548429 |
| Occupational Environmental Medicine | 0.553867 |
| Mortality among | 0.531703 |
| Occupational Safety | 0.816569 |
| materiales aislantes | 0.528932 |
| British chemical workers | 0.549313 |
| Emergency Management Agency | 0.637566 |
| vÃas respiratorias | 0.526175 |
| National Cancer Institute | 0.733699 |
| National Institute | 0.579158 |
| aislamiento tipo uffi | 0.553887 |
| Health Administration | 0.662185 |
| Consumer Product Safety | 0.833221 |
| Indoor Environments Division | 0.548156 |
| corto plazo | 0.574665 |
| garment workers | 0.530046 |
| Blair A | 0.564637 |
| cabo estudios | 0.530631 |
| 12.º informe | 0.526826 |
| Federal Emergency Management | 0.627002 |
| Institutos Nacionales | 0.577211 |
|
CLICK HERE |
| 15882 |
National Cancer Institute |
Html |
es |
Cardo mariano (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso del cardo mariano como tratamiento para personas con cáncer. |
| Silybum marianum | 0.735385 |
| Agarwal R | 0.945743 |
| cell lines | 0.375003 |
| cell growth | 0.494513 |
| prostate carcinoma du145 | 0.373715 |
| DNA synthesis | 0.442196 |
| carcinoma cell | 0.46955 |
| silybum marianum l | 0.361146 |
| Inhibitory effect | 0.390679 |
| Agarwal C | 0.386743 |
| receptor modulator activity | 0.356592 |
| Mol Carcinog | 0.378538 |
| Cancer Res | 0.59348 |
| carcinoma cell growth | 0.407562 |
| prostate carcinoma cells | 0.4865 |
| Singh RP | 0.367955 |
| flavonoid antioxidant | 0.678831 |
| active constituent | 0.382485 |
| Antiproliferative effect | 0.363827 |
| lipid peroxidation | 0.585387 |
| Biochem Pharmacol | 0.461277 |
| chemopreventive effects | 0.369648 |
| cardo lechero | 0.365629 |
| patients with | 0.374862 |
| cell growth inhibition | 0.393232 |
|
| Sonnenbichler J | 0.428511 |
| prostate carcinoma | 0.590474 |
| Campos R | 0.414926 |
| Pharmacol Res | 0.429959 |
| protective effects | 0.379153 |
| Biophys Res Commun | 0.50103 |
| prostate-specific antigen with | 0.369145 |
| carcinoma du145 cells | 0.397873 |
| Biochem Biophys Res | 0.508991 |
| Silymarin effects | 0.38621 |
| Biomed Res Int | 0.385769 |
| Clin Biol Res | 0.375557 |
| insulin-like growth factor-binding | 0.358425 |
| stimulatory effects | 0.357205 |
| Zhao J | 0.53049 |
| Guerra R | 0.490633 |
| with cell growth | 0.41107 |
| comparison with | 0.378495 |
| silibinin inhibits | 0.378656 |
| Planta Med | 0.529049 |
| protects against | 0.371646 |
| Mutat Res | 0.369799 |
| from silybum marianum | 0.396284 |
| Res Commun | 0.505421 |
|
CLICK HERE |
| 16247 |
National Cancer Institute |
Html |
en |
Examining the Effects of Presurgical Treatment for Prostate Cancer |
In this study, men diagnosed with androgen-sensitive prostate cancer with intermediate- or high-risk features will be examined with mpMRI, undergo targeted biopsies, and be treated with neoadjuvant androgen deprivation therapy. |
| prostate tumors | 0.614738 |
| mpMRI scans | 0.310993 |
| new strategies | 0.267582 |
| potential tumor markers | 0.311786 |
| clinical trials | 0.372782 |
| targeted biopsy samples | 0.322875 |
| targeted lesions | 0.294339 |
| specific prostate lesions | 0.476878 |
| high-risk features | 0.288054 |
| newly diagnosed prostate | 0.622232 |
| metastatic prostate cancer | 0.498919 |
| prostate cancer cells | 0.594259 |
| surgically removed organs | 0.312098 |
| antiandrogen drug enzalutamide | 0.322935 |
| single imaging exam | 0.312805 |
| Dr. William Dahut | 0.330786 |
| systemic therapy | 0.28819 |
| neoadjuvant therapy | 0.769289 |
| aggressive prostate cancers | 0.483417 |
| protocol summary | 0.275419 |
| androgen-deprivation therapy | 0.285401 |
| NCI Center | 0.275353 |
| magnetic resonance imaging | 0.315153 |
| trial contact information | 0.309223 |
| United States | 0.272406 |
|
| intensive hormonal therapy | 0.397524 |
| high-risk prostate tumors | 0.477739 |
| prostatectomy specimens | 0.282563 |
| Treating Patients | 0.272894 |
| initial mpMRI scans | 0.308885 |
| high-risk prostate cancer | 0.602491 |
| radical prostatectomy | 0.351855 |
| NCI Clinical Trials | 0.312784 |
| common malignancy | 0.274438 |
| androgen-sensitive prostate cancer | 0.480836 |
| potential strategy | 0.266185 |
| Cancer Research | 0.343151 |
| anatomic imaging | 0.268037 |
| drug goserelin actetate | 0.309432 |
| targeted biopsies | 0.292493 |
| male sex hormones | 0.320468 |
| Goserelin Acetate | 0.270879 |
| high-risk disease | 0.33068 |
| prostate cancer | 0.95691 |
| neoadjuvant ADT | 0.340784 |
| aggressive disease | 0.267926 |
| prostate cancer recurrence | 0.502931 |
| specific lesions | 0.287557 |
| effective neoadjuvant therapy | 0.348548 |
|
CLICK HERE |
| 17173 |
National Cancer Institute |
Html |
es |
Hongos medicinales (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de los hongos medicinales como tratamiento para las personas con cáncer. |
| adjuvant immunochemotherapy with | 0.310705 |
| ganoderma lucidum | 0.95261 |
| Coriolus versicolor | 0.338242 |
| Ganoderma lucidum from | 0.330019 |
| triterpenoids from ganoderma | 0.34341 |
| from ganoderma spp | 0.316446 |
| extracted from ganoderma | 0.316294 |
| Se-enriched Ganoderma lucidum | 0.325078 |
| mushroom ganoderma lucidum | 0.326878 |
| cuáles pacientes | 0.311657 |
| adjuvant immunochemotherapy | 0.310969 |
| cells with immuno-stimulatory | 0.308341 |
| PSK may | 0.326201 |
| polysaccharides from ganoderma | 0.316147 |
| Ganoderma lucidum induces | 0.347342 |
| Oncol Rep | 0.321721 |
| Ganoderma lucidum polysaccharides | 0.378912 |
| Ganoderma lucidum mycelia | 0.327066 |
| pacientes supervivencia | 0.312919 |
| Ganoderma polysaccharides with | 0.315786 |
| patients with | 0.347196 |
| protein-bound polysaccharide psk | 0.327993 |
| lz-8 from ganoderma | 0.316148 |
| Ganoderma lucidum activities | 0.328306 |
| metabolites from ganoderma | 0.315749 |
|
| ganoderma lingzhi wu | 0.315644 |
| PSK quizás | 0.327997 |
| Ganoderma lucidum spores-induced | 0.32738 |
| from ganoderma lucidum | 0.482816 |
| oficiales ganoderma lucidum | 0.327352 |
| immunochemotherapy with psk | 0.347115 |
| PSK therapies | 0.324706 |
| isolated from ganoderma | 0.330138 |
| commercial ganoderma | 0.31277 |
| lucidum suppresses angiogenesis | 0.315879 |
| Ganoderma based | 0.312698 |
| ganoderma sinense zhao | 0.315248 |
| Mol Med | 0.308288 |
| gastric cancer | 0.374999 |
| extract from ganoderma | 0.316948 |
| immunochemotherapy with polysaccharide | 0.311361 |
| breast cancer | 0.314008 |
| Mushroom Science | 0.307833 |
| Ganoderma lingzhi from | 0.316096 |
| ganoderma lucidum triterpenoids | 0.328168 |
| PSK potencia | 0.327619 |
| Ganoderma lingzhi | 0.323758 |
| leukemia cells | 0.314028 |
| estudios cáncer | 0.308153 |
|
CLICK HERE |